21.07.2025 • NewsHarkeHarke GroupThorsten Harke

Harke Acquires Swedish Vendico

Harke Group, a high-performance chemicals and plastics distributor based in Mülheim an der Ruhr, Germany, acquired the Swedish Vendico Group, comprising Vendico Chemical, Inventicon, and Omni International.

Thorsten Harke
Thorsten Harke, President of Harke Group
© Harke Group

Vendico Group represents several dozen leading manufacturers of chemical raw materials in the Personal Care, Home Care, and I&I sectors, as well as other applications. It has a broad range of chemicals that are directed towards many branches of the Nordic chemical industry, with a strong foothold on companies working with surface active applications.

Thorsten Harke, President of Harke Group commented: “With the acquisition of Vendico Group, we further strengthen our presence in the Nordic chemical distribution market. Vendico Group fits perfectly to Harke Group. Not only concerning the regions it covers — Sweden, Denmark, Norway, Finland, Iceland and the Baltic region. But also from its product range and the principals it represents, of which many had been cooperating with Harke Group before already. By combining the two company groups we can now offer an even better coverage and service to our customers and principals throughout Europe and Asia.”

Company

Logo:

Harke Group GmbH

Xantener Str. 1
45479 Mülheim
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read